Cargando…

Optimized therapeutic strategy for patients with refractory or relapsed acute myeloid leukemia: long‐term clinical outcomes and health‐related quality of life assessment

BACKGROUND: Patients with refractory or relapsed acute myeloid leukemia (AML) have poor survival, necessitating the exploration of optimized therapeutic strategy. Here, we aimed to investigate clinical outcomes and health‐related quality of life (HR‐QoL) after total therapy, which included allogenei...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yan, Chen‐hua, Wang, Yu, Sun, Yu‐qian, Cheng, Yi‐fei, Mo, Xiao‐dong, Wang, Feng‐rong, Chen, Yu‐hong, Zhang, Yuan‐yuan, Han, Ting‐ting, Chen, Huan, Xu, Lan‐ping, Zhang, Xiao‐hui, Liu, Kai‐yan, Huang, Xiao‐jun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9759766/ https://www.ncbi.nlm.nih.gov/pubmed/36274263 http://dx.doi.org/10.1002/cac2.12376

Ejemplares similares

High aldehyde dehydrogenase activity at diagnosis predicts relapse in patients with t(8;21) acute myeloid leukemia
por: Yang, Lu, et al.
Publicado: (2019)

Improved outcome of children with relapsed/refractory acute myeloid leukemia by addition of cladribine to re‐induction chemotherapy
por: Ruan, Min, et al.
Publicado: (2021)

The dynamics of RUNX1-RUNX1T1 transcript levels after allogeneic hematopoietic stem cell transplantation predict relapse in patients with t(8;21) acute myeloid leukemia
por: Qin, Ya-Zhen, et al.
Publicado: (2017)

Efficacy of common salvage chemotherapy regimens in patients with refractory or relapsed acute myeloid leukemia: A retrospective cohort study
por: Xu, Jun, et al.
Publicado: (2018)

P573: NOVEL PROGNOSTIC MODEL FOR RELAPSE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA RECEIVING HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION
por: Wen, Qi, et al.
Publicado: (2023)

Preemptive Interferon-α Therapy Could Protect Against Relapse and Improve Survival of Acute Myeloid Leukemia Patients After Allogeneic Hematopoietic Stem Cell Transplantation: Long-Term Results of Two Registry Studies
por: Shen, Meng-Zhu, et al.
Publicado: (2022)

A risk score system for stratifying the risk of relapse in B cell acute lymphocytic leukemia patients after allogenic stem cell transplantation
por: Cao, Le-Qing, et al.
Publicado: (2021)

Chidamide increases the sensitivity of refractory or relapsed acute myeloid leukemia cells to anthracyclines via regulation of the HDAC3 -AKT-P21-CDK2 signaling pathway
por: Wang, Hao, et al.
Publicado: (2020)

Association of Persistent Minimal Residual Disease with Poor Outcomes of Patients with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
por: Liu, Jing, et al.
Publicado: (2018)

A Predicted Model for Refractory/Recurrent Cytomegalovirus Infection in Acute Leukemia Patients After Haploidentical Hematopoietic Stem Cell Transplantation
por: Shen, Meng-Zhu, et al.
Publicado: (2022)

Minimal residual disease- and graft-vs.-host disease-guided multiple consolidation chemotherapy and donor lymphocyte infusion prevent second acute leukemia relapse after allotransplant
por: Yan, Chen-Hua, et al.
Publicado: (2016)

Current Approaches in the Treatment of Relapsed and Refractory Acute Myeloid Leukemia
por: Ramos, Nestor R., et al.
Publicado: (2015)

Correction to: Minimal residual disease- and graft-vs.-host disease-guided multiple consolidation chemotherapy and donor lymphocyte infusion prevent second acute leukemia relapse after allotransplant
por: Yan, Chen-Hua, et al.
Publicado: (2019)

Treatment for Relapsed/Refractory Acute Myeloid Leukemia
por: Thol, Felicitas, et al.
Publicado: (2021)

A Retrospective Observation of Treatment Outcomes Using Decitabine-Combined Standard Conditioning Regimens Before Transplantation in Patients With Relapsed or Refractory Acute Myeloid Leukemia
por: Li, Yuhang, et al.
Publicado: (2021)

Wilms’ tumor gene 1 is an independent prognostic factor for pediatric acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation
por: Deng, Dao-Xing, et al.
Publicado: (2021)

Efficacy and toxicity of CLAG combined with pegylated liposomal doxorubicin in the treatment of refractory or relapsed acute myeloid leukemia
por: Yao, Han, et al.
Publicado: (2023)

PB1850: MITOXANTRONE HYDROCHLORIDE LIPOSOME INJECTION COMBINED WITH CLAG REGIMEN IN REFRACTORY AND RELAPSED ACUTE MYELOID LEUKEMIA (NON-M3)
por: Wan, Kai, et al.
Publicado: (2023)

Monitoring of post-transplant MLL-PTD as minimal residual disease can predict relapse after allogeneic HSCT in patients with acute myeloid leukemia and myelodysplastic syndrome
por: Kong, Jun, et al.
Publicado: (2022)

Preemptive Immunotherapy for Minimal Residual Disease in Patients With t(8;21) Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation
por: Fan, Shuang, et al.
Publicado: (2022)

Pembrolizumab and decitabine for refractory or relapsed acute myeloid leukemia
por: Goswami, Meghali, et al.
Publicado: (2022)

Preemptive interferon-α therapy could prevent relapse of acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation: A real-world analysis
por: Fan, Shuang, et al.
Publicado: (2023)

Venetoclax with Decitabine or Azacitidine in Relapsed or Refractory Acute Myeloid Leukemia
por: Bouligny, Ian M., et al.
Publicado: (2023)

A Phase II Trial of the Double Epigenetic Priming Regimen Including Chidamide and Decitabine for Relapsed/Refractory Acute Myeloid Leukemia
por: Yin, Jia, et al.
Publicado: (2021)

Venetoclax-based therapy for relapsed or refractory acute myeloid leukemia: latest updates from the 2022 ASH annual meeting
por: Gong, Xubo, et al.
Publicado: (2023)

First-in-human phase I study of CLL-1 CAR-T cells in adults with relapsed/refractory acute myeloid leukemia
por: Jin, Xin, et al.
Publicado: (2022)

Phase 1 study of vibecotamab identifies an optimized dose for treatment of relapsed/refractory acute myeloid leukemia
por: Ravandi, Farhad, et al.
Publicado: (2023)

Low IL7R Expression at Diagnosis Predicted Relapse in Adult Acute Myeloid Leukemia Patients With t(8;21)
por: Xu, Nan, et al.
Publicado: (2022)

Efficacy and Safety of Unmanipulated Haploidentical Related Donor Allogeneic Peripheral Blood Stem Cell Transplantation in Patients with Relapsed/Refractory Acute Myeloid Leukemia
por: Dou, Li-Ping, et al.
Publicado: (2018)

The hypomethylating agent decitabine prior to chemotherapy improves the therapy efficacy in refractory/relapsed acute myeloid leukemia patients
por: Jiang, Xuejie, et al.
Publicado: (2015)

Analysis of the Clinical Efficacy of Azacytidine + Venetoclax in the Treatment of Elderly Patients with Relapsed Refractory Acute Myeloid Leukemia
por: Wang, Wei, et al.
Publicado: (2022)

B Cell Deficiency in Patients with Relapsed and Refractory Acute Myeloid Leukemia
por: Goswami, Meghali, et al.
Publicado: (2020)

Timed Sequential Salvage Chemotherapy for Relapsed or Refractory Acute Myeloid Leukemia
por: Popescu, Bogdan, et al.
Publicado: (2019)

Recent advances of targeted therapy in relapsed/refractory acute myeloid leukemia
por: Ma, Jiale, et al.
Publicado: (2021)

Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia: Are Supporting Evidences Enough?
por: Brancati, Serena, et al.
Publicado: (2021)

Targeting Glutamine Metabolism as an Attractive Therapeutic Strategy for Acute Myeloid Leukemia
por: Xiao, Yan, et al.
Publicado: (2023)

Feasibility of high-throughput drug sensitivity screening (HDS)-guided treatment for children with refractory or relapsed acute myeloid leukemia
por: Lv, Wenxiu, et al.
Publicado: (2023)

CAG regimen for refractory or relapsed adult T‐cell acute lymphoblastic leukemia: A retrospective, multicenter, cohort study
por: Qian, Jie‐Jing, et al.
Publicado: (2020)

Reassessing the role of high dose cytarabine and mitoxantrone in relapsed/refractory acute myeloid leukemia
por: Canaani, Jonathan, et al.
Publicado: (2020)

Measurable Residual Disease Detected by Multiparameter Flow Cytometry and Sequencing Improves Prediction of Relapse and Survival in Acute Myeloid Leukemia
por: Liu, Fu-Jia, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_3lluh7fmiai1hkie21g7s9pdfn